Is compounded tirzepatide still available?

Three meanings of available

An offer can be advertised online, a clinician can evaluate a request, and a pharmacy can fulfill a particular prescription. Those are different milestones. The continued existence of a price page establishes the first only. A completed checkout does not establish the clinical decision or the legal eligibility and availability of the specific preparation. The question needs an answer from the organizations responsible for the latter steps. [5][6]

Our access roster shows the provider advertisements recorded in the directory, with the original source dates. It is not live pharmacy inventory or a list of individually authorized prescriptions. Use it to identify services to contact and the evidence behind their claims. Do not assume an article prepared today refreshes a company page checked on an earlier date. [1][2][3]

The shortage-related timeline is historical

FDA’s tirzepatide chronology describes its shortage-resolution decisions and subsequent temporary enforcement arrangements. Those dated windows are relevant to why earlier compounded programs existed and why some changed. They are not permanent permission attached to an ingredient name. FDA’s April 2026 reminder is the current source used here for the list status and pathway conditions. [4]

The reminder states that tirzepatide is not on the shortage list or 503B bulks list. FDA’s published bulk-substance list should be read separately from the outsourcing-facility registration list. A company naming a registered facility does not establish that tirzepatide qualifies for bulk compounding at that facility. The records concern different entities and legal questions. [4][7][8]

503A does not mean unrestricted copying

For 503A, FDA highlights the individual-patient prescription requirement and limits on regularly or in inordinate amounts producing essentially copies of commercial drugs. The policy discusses a prescriber-documented change that produces a significant difference for an identified patient. That framework is more specific than a provider saying it offers customized care or that a prescription is cheaper than a branded package. [4]

Ask the actual prescribing and dispensing organizations what preparation is being considered and how they address the relevant requirements. A directory cannot inspect the pharmacy’s operation or establish the documentation for an individual patient. We do not convert an advertisement into permission or state that all patient-specific compounding has disappeared. Both blanket claims would hide the conditions the current source actually describes. [9][5]

503B has its own bulk and copy constraints

FDA describes outsourcing-facility restrictions involving the 503B bulks list and shortage status at the required stages of production and dispensing. A registration claim cannot replace that eligibility check. FDA’s April 2026 GLP-1 bulks announcement also describes a proposal; this article does not independently establish it as a final action. The current list and policy reminder are the basis for the statement above. [7][10][4]

Facility oversight and product approval must also remain distinct. A registered outsourcing facility is a regulated category, not a manufacturer approval for every compounded drug it makes. FDA’s compounding questions distinguish compounded products from approved drugs regardless of the setting. The preparation does not become an approved generic Zepbound or Mounjaro because the pharmacy has a registration. [8][5]

Your state and the actual product need confirmation

A provider may advertise service in a state while offering only some products or using different pharmacy partners by location. Use the medication-state page for the directory’s documented coverage policy and recorded exclusions, then ask the provider about the current product-specific arrangement. General service evidence is not the same as a direct statement that the proposed preparation can be dispensed to an individual patient there. [6][3]

An online request must still undergo clinician evaluation. Ask whether the charge occurs before that decision and what happens if the program does not result in a prescription. A financial refund policy does not determine legal eligibility for compounding, but it matters when deciding whether to authorize a payment for a request still under review. The signup checklist keeps that contractual question separate. [11][5]

What changed access means for a price comparison

A recorded compounded quote can remain useful historical price evidence even if the provider later changes its offer. That is why the table keeps the check date and links the primary source rather than presenting it as a guaranteed current order. Compare the actual quote for the preparation proposed after evaluation, including the commitment and missing charges. A lower recorded price is not proof of current lawful availability. [1][2][11]

If the service no longer offers the recorded preparation, ask the clinician and pharmacy about their current process rather than seeking a no-prescription seller. FDA BeSafeRx provides licensing and valid-prescription checks, while FDA’s GLP-1 concerns page distinguishes illicit products sold under research labels. This guide reports access categories and regulatory conditions, not alternatives for changing a treatment plan yourself. [6][12]

The dated tirzepatide enforcement milestones

FDA’s chronology includes its December 19, 2024 renewed shortage-resolution decision after reevaluation. The February 2025 update described the 503A and 503B windows with litigation-related qualifications. The March 10, 2025 update then said the 503A period had ended after the court decision and retained the 503B window through March 19, 2025. These dates explain why an older February deadline in an article is not the whole history. None creates a new October 2026 shortage exemption. Current access claims need the newest conditions, not an isolated early transition announcement. [4]